Abstracts tagged "cytokines and rheumatoid arthritis (RA)"

Abstract Number: 720 • 2013 ACR/ARHP Annual Meeting
Abatacept Efficacy Is Overruled By IL-7 In TSLP-Primed Myeloid Dendritic cell driven T Cell Activation From Rheumatoid Arthritis Patients
F.M. Moret¹, T.R.D.J. Radstake², J.W.J. Bijlsma¹, F.P.J.G. Lafeber³ and J.a.G. van Roon⁴, ¹Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, Netherlands, ⁴Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Abatacept is an effective treatment for a subset of rheumatoid arthritis (RA) patients, interfering in the interaction between antigen-presenting cells and T cells preventing…
Abstract Number: 1727 • 2013 ACR/ARHP Annual Meeting
Novel Selective Inhibitors Of Nuclear Export Attenuate Inflammation and Prevent Bone Mineral Density Loss In Multiple Preclinical Models Of Rheumatoid Arthritis
Mwanasha Hamuza¹, Yosef Landesman¹, Boris Klebanov¹, Michael Kauffman¹, Sharon Shacham¹, Judith Endres², David A. Fox³ and Dilara McCauley¹, ¹Karyopharm Therapeutics Inc., Natick, MA, ²Rheumatology/Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, ³Rheumatology/Int Medicine, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Exportin 1 (XPO1; also called chromosome region maintenance 1, CRM1) is a key protein that controls the export of ~220 cargo proteins and several…
Abstract Number: 1459 • 2013 ACR/ARHP Annual Meeting
Multiple Cytokine Profiling Predicts The Effectiveness Of Switching Biologics In Rheumatoid Arthritis
Kensuke Koyama¹, Katsunori Ikari¹, Atsuo Taniguchi², Shigeki Momohara² and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: There is some rheumatoid arthritis (RA) patients with poor responses to certain biologics which requires switching to another biologics. However, there is no solid…
Abstract Number: 1388 • 2013 ACR/ARHP Annual Meeting
Multiplex Cytokine Analyses In Patients With Rheumatoid Arthritis Require Use Of Agents Blocking Heterophilic Antibody Activity
Peter Olsson¹, Elke Theander², Ulf Bergström³, Stefan Jovinge⁴, Lennart Jacobsson³ and Carl Turesson², ¹Section of Rheumatology, Department of Clinical Sciences, Lund University, Malmö, Sweden, ²Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ³Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁴Strategic Research Center for Stem Cell Biology and Cell Therapy, Lund University, Lund, Sweden
Background/Purpose: Rheumatoid factor (RF) and other circulating heterophilic antibodies have been shown to interfere with antibody-based immunoassays, in particular with multiplex protein detection platforms. Previous…
Abstract Number: 2162 • 2012 ACR/ARHP Annual Meeting
Correlation of A Multi-Biomarker Disease Activity (VECTRA™ DA) Score with Clinical Disease Activity and Its Components with Radiographic Progression in Rheumatoid Arthritis Patients Treated with Tofacitinib
Kunihiro Yamaoka¹, Satoshi Kubo¹, Koshiro Sonomoto¹, Shintaro Hirata¹, Guy Cavet², Rebecca Bolce², Michael W. Rowe², David Chernoff², Nadine Defranoux², Kazuyoshi Saito¹ and Yoshiya Tanaka¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose: A multi-biomarker disease activity (MBDA) score has been developed for evaluation of disease activity of rheumatoid arthritis (RA) to complement clinical assessment and to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].